-
3
-
-
0342575637
-
-
Washington, DC: The Progress and Freedom Foundation; February 7
-
Epstein RA, Lenard TM, Miller HI, Tollison RD, Viscusi WK, Wardell WM. Advancing medical innovation: health, safety and the role of government in the 21st century. Washington, DC: The Progress and Freedom Foundation; February 7, 1996.
-
(1996)
Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century
-
-
Epstein, R.A.1
Lenard, T.M.2
Miller, H.I.3
Tollison, R.D.4
Viscusi, W.K.5
Wardell, W.M.6
-
5
-
-
1842375152
-
-
Washington, DC: Pharmaceutical Research and Manufacturers of America; May
-
The Patient is Waiting. Washington, DC: Pharmaceutical Research and Manufacturers of America; May 1996.
-
(1996)
The Patient Is Waiting
-
-
-
9
-
-
0343427072
-
-
Pub law 102-571 (1992 Oct 29); 21 USC 379; 106 Stat 4491
-
Prescription Drug User Fee Act of 1992. Pub law 102-571 (1992 Oct 29); 21 USC 379; 106 Stat 4491.
-
Prescription Drug User Fee Act of 1992
-
-
-
10
-
-
1842291077
-
FDA/industry user fee reauthorization bill to address clinical holds, meeting requests; other FDA reform proposals under discussion on Feb. deadline
-
Dec 9
-
FDA/industry user fee reauthorization bill to address clinical holds, meeting requests; other FDA reform proposals under discussion on Feb. deadline. The Pink Sheet. 1996 Dec 9;58(50):3.
-
(1996)
The Pink Sheet
, vol.58
, Issue.50
, pp. 3
-
-
-
11
-
-
0030033574
-
The Prescription Drug User Fee Act of 1992: A five-year experiment for industry and the FDA
-
Shulman SR, Kaitin KI. The Prescription Drug User Fee Act of 1992: a five-year experiment for industry and the FDA. PharmacoEcon. 1996;9:121-133.
-
(1996)
PharmacoEcon.
, vol.9
, pp. 121-133
-
-
Shulman, S.R.1
Kaitin, K.I.2
-
12
-
-
0029967936
-
A new look at United States drug development and approval times
-
DiMasi JA. A new look at United States drug development and approval times. Am J Ther. 1996;3(9): 1-11.
-
(1996)
Am J Ther.
, vol.3
, Issue.9
, pp. 1-11
-
-
DiMasi, J.A.1
-
14
-
-
0030947897
-
The new drug approvals of 1993, 1994, and 1995: Trends in drug development
-
Jan
-
Kaitin KI, Manocchia MA. The new drug approvals of 1993, 1994, and 1995: trends in drug development. Am J Ther. 1997 Jan;4(1):46-54.
-
(1997)
Am J Ther.
, vol.4
, Issue.1
, pp. 46-54
-
-
Kaitin, K.I.1
Manocchia, M.A.2
-
15
-
-
0030951929
-
The Prescription Drug User Fee Act of 1992 and the new drug development process
-
May
-
Kaitin KI. The Prescription Drug User Fee Act of 1992 and the new drug development process. Am J Ther. 1997 May;4(5).
-
(1997)
Am J Ther.
, vol.4
, Issue.5
-
-
Kaitin, K.I.1
-
17
-
-
1842413765
-
Content and format of an application
-
Content and format of an application. 21 CFR 314.50.
-
CFR
, vol.21
, pp. 31450
-
-
-
18
-
-
0347338821
-
Subpart B - Investigational new drug application
-
Subpart B - investigational new drug application. 21 CFR 312.20-312.38.
-
CFR
, vol.21
, pp. 31220-31238
-
-
-
19
-
-
1842338155
-
Drugs intended to treat life-threatening and severely debilitating illness
-
Drugs intended to treat life-threatening and severely debilitating illness. 21 CFR 312.80.
-
CFR
, vol.21
, pp. 31280
-
-
-
20
-
-
0026028210
-
Therapeutic ratings and end-of-phase II conferences: Initiatives to accelerate availability of important new drugs
-
Kaitin KI, Phelan NR, Raiford D, Morris B. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate availability of important new drugs. J Clin Pharmacol. 1991;31(1):17-24.
-
(1991)
J Clin Pharmacol.
, vol.31
, Issue.1
, pp. 17-24
-
-
Kaitin, K.I.1
Phelan, N.R.2
Raiford, D.3
Morris, B.4
-
21
-
-
0026691466
-
Are initiatives to speed the new drug approval process working?
-
Kaitin KI, Walsh HL. Are initiatives to speed the new drug approval process working? Drug Inf J. 1992;26:341-349.
-
(1992)
Drug Inf J.
, vol.26
, pp. 341-349
-
-
Kaitin, K.I.1
Walsh, H.L.2
-
22
-
-
0028455313
-
New drug development in the United States from 1963 to 1992
-
DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther. 1994;55(6):609-622.
-
(1994)
Clin Pharmacol Ther.
, vol.55
, Issue.6
, pp. 609-622
-
-
DiMasi, J.A.1
Seibring, M.A.2
Lasagna, L.3
-
23
-
-
0028895424
-
Research and development costs for new drugs by therapeutic category: A study of the US pharmaceutical industry
-
DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. PharmacoEcon. 1995;7(2):152-169.
-
(1995)
PharmacoEcon.
, vol.7
, Issue.2
, pp. 152-169
-
-
DiMasi, J.A.1
Hansen, R.W.2
Grabowski, H.G.3
Lasagna, L.4
-
24
-
-
1842328703
-
Treatment use of an investigational new drug
-
Treatment use of an investigational new drug. 21 CFR 312.34.
-
CFR
, vol.21
, pp. 31234
-
-
-
25
-
-
0029555624
-
The Food and Drug Administration's early access and fast-track approval initiatives: How have they worked?
-
Shulman SR, Brown JS. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked? Food and Drug Law J. 1995;50(4):503-531.
-
(1995)
Food and Drug Law J.
, vol.50
, Issue.4
, pp. 503-531
-
-
Shulman, S.R.1
Brown, J.S.2
-
26
-
-
0024352604
-
FDA advisory committees and the new drug approval process
-
Kaitin KI, Melville A, Morris B. FDA advisory committees and the new drug approval process. J Clin Pharmacol. 1989;29:886-890.
-
(1989)
J Clin Pharmacol.
, vol.29
, pp. 886-890
-
-
Kaitin, K.I.1
Melville, A.2
Morris, B.3
-
27
-
-
0003022674
-
R&D costs, innovative output, and firm size in the pharmaceutical industry
-
DiMasi JA, Grabowski HG, Vernon J. R&D costs, innovative output, and firm size in the pharmaceutical industry. Int J Econ Bus. 1995;2(2):201-219.
-
(1995)
Int J Econ Bus.
, vol.2
, Issue.2
, pp. 201-219
-
-
DiMasi, J.A.1
Grabowski, H.G.2
Vernon, J.3
-
28
-
-
0343245999
-
-
(GAO/PEMD-96-1) Washington, DC: United States General Accounting Office; Oct
-
FDA drug approval: review time has decreased in recent years. (GAO/PEMD-96-1) Washington, DC: United States General Accounting Office; Oct 1995.
-
(1995)
FDA Drug Approval: Review Time Has Decreased in Recent Years
-
-
-
31
-
-
1842409673
-
Formal Meetings between CDER and CDER's External Constituents
-
MAPP 4512.1, Rockville, MD: Food and Drug Administration; Mar 3
-
Formal Meetings Between CDER and CDER's External Constituents. Manual of Policies and Procedures, Center for Drug Evaluation and Research, Office of Training and Communications, Food and Drug Administration. MAPP 4512.1, Rockville, MD: Food and Drug Administration; Mar 3, 1996.
-
(1996)
Manual of Policies and Procedures, Center for Drug Evaluation and Research, Office of Training and Communications, Food and Drug Administration
-
-
-
32
-
-
1842299970
-
FDA/industry "PDUFA II" proposal would cut NDA review deadline from 12 to 10 months; NAPM to begin discussing generic user fees with agency & Congress
-
Feb 3
-
FDA/industry "PDUFA II" proposal would cut NDA review deadline from 12 to 10 months; NAPM to begin discussing generic user fees with agency & Congress. The Pink Sheet. 1997 Feb 3;59(5):6-7.
-
(1997)
The Pink Sheet
, vol.59
, Issue.5
, pp. 6-7
-
-
|